Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08EIK
|
|||
Former ID |
DIB012622
|
|||
Drug Name |
LY3016859
|
|||
Synonyms |
TGF-alpha.epiregulin mAb
Click to Show/Hide
|
|||
Indication | Chronic kidney disease [ICD-11: GB61; ICD-10: N18, N18.9] | Phase 1/2 | [1] | |
Company |
Eli lilly
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Epiregulin (EREG) | Target Info | Modulator | [2] |
Transforming growth factor alpha (TGFA) | Target Info | Modulator | [2] | |
KEGG Pathway | ErbB signaling pathway | |||
NetPath Pathway | FSH Signaling Pathway | |||
EGFR1 Signaling Pathway | ||||
Panther Pathway | EGF receptor signaling pathway | |||
Pathway Interaction Database | ErbB4 signaling events | |||
ErbB receptor signaling network | ||||
Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
Cargo concentration in the ER | ||||
SHC1 events in ERBB2 signaling | ||||
PI3K events in ERBB4 signaling | ||||
SHC1 events in ERBB4 signaling | ||||
Nuclear signaling by ERBB4 | ||||
PIP3 activates AKT signaling | ||||
GRB2 events in ERBB2 signaling | ||||
PI3K events in ERBB2 signaling | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
RAF/MAP kinase cascade | ||||
WikiPathways | ErbB Signaling Pathway | |||
NRF2 pathway | ||||
Nuclear Receptors Meta-Pathway | ||||
Extracellular vesicle-mediated signaling in recipient cells | ||||
Signaling by ERBB4 | ||||
Signaling by ERBB2 | ||||
PIP3 activates AKT signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01774981) Study of LY3016859 in Participants With Diabetic Nephropathy. U.S. National Institutes of Health. | |||
REF 2 | Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.